{"id":1093,"date":"2021-10-04T15:24:53","date_gmt":"2021-10-04T15:24:53","guid":{"rendered":"https:\/\/acemesclerosis.org\/?page_id=1093"},"modified":"2025-04-16T09:33:27","modified_gmt":"2025-04-16T09:33:27","slug":"esclerose","status":"publish","type":"page","link":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl","title":{"rendered":"Esclerose"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
<\/div>
<\/div><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

esclerose m\u00faltiple<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t

A esclerose m\u00faltiple \u00e9 unha enfermidade cr\u00f3nica do Sistema Nervioso Central (SNC), que afecta, de maneira intermitente, \u00e1 sustancia branca (mielina) de medula espinal e ao cerebro.<\/p>

Nos lugares afectados alt\u00e9rase a vaina de mielina que recubre os nervios. Como consecuencia disto atr\u00e1sase ou se interrompe a comunicaci\u00f3n nerviosa, xa que a mielina queda substitu\u00edda por placas de tecido endurecido (esclerose). Debido a que esta destruci\u00f3n leva a cabo en diferentes e m\u00faltiples lugares, a enfermidade \u00e9 chamada Esclerose M\u00faltiple.<\/p>

Esta enfermidade pode aparecer en calquera etapa da vida e en ambos os sexos, a\u00ednda que \u00e9 m\u00e1is frecuente en mulleres e entre a poboaci\u00f3n adulta nova. A maior\u00eda dos casos diagnost\u00edcanse en persoas que te\u00f1en entre 20 e 40 anos de idade a\u00ednda que tam\u00e9n pode aparecer en nenos, adolescentes e anci\u00e1ns.<\/p>

Os s\u00edntomas m\u00e1is habituais son:<\/p>

  • Afectaci\u00f3n da vista.<\/li>
  • Fatiga<\/li>
  • Espasticidade.<\/li>
  • Problemas de equilibrio<\/li>
  • Problemas de incontinencia<\/li>
  • Perda de forza ou sensibilidade en algures do corpo.<\/li>
  • Alteraci\u00f3ns de memoria e concentraci\u00f3n<\/li>
  • Alteraci\u00f3ns da fala e degluci\u00f3n.<\/li><\/ul>

    \u00a0<\/p>

    Estes s\u00edntomas poden aparecer no que se denominan brotes e desaparecen total ou parcialmente despois. Non todos os s\u00edntomas aparecen en todas as persoas, nin o fan coa mesma intensidade. Este \u00e9 o motivo polo que se presenta en cada persoa de forma distinta e ad\u00f3itase denominar como \u201ca enfermidade do mil caras\u201d<\/p><\/div><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    remitente recorrente<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t

    \u00c9 o tipo m\u00e1is frecuente de Esclerose M\u00faltiple e afecta a m\u00e1is do 80% das persoas<\/strong> que ten a enfermidade. Na EM remitente-recorrente (EMRR) os s\u00edntomas ocorren en forma de brotes <\/strong>que aparecen durante un per\u00edodo de tempo m\u00ednimo de 24 horas e se poden alargar durante d\u00edas, semanas ou mesmo meses, logo melloran parcial ou totalmente. Nalgunha ocasi\u00f3n, os brotes poden deixar secuelas neurol\u00f3gicas.<\/p><\/div><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    primaria
    progresiva<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n
    \n\nA Esclerose M\u00faltiple Primaria Progresiva (EMPP) \u00e9 un tipo pouco frecuente de EM que afecta a entre un 10 e un 15% dos pacientes<\/strong> diagnosticados. Caracter\u00edzase pola ausencia de brotes definidos <\/strong>(ao contrario que a forma remitente-recorrente), pero hai un comezo lento e un empeoramento constante<\/strong> dos s\u00edntomas sen un per\u00edodo intermedio de remisi\u00f3n.\n\nNo caso das persoas con este tipo de Esclerose M\u00faltiple, as alteraci\u00f3ns permanecen e progresan. Isto non impide que nalg\u00fans per\u00edodos a enfermidade estabil\u00edcese, mesmo, que a persoa experimente algunha mellor\u00eda, pero a tendencia xeral \u00e9 cara \u00e1 progresi\u00f3n.\n\n<\/div>\n<\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    primaria
    progresiva<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    secundaria progresiva<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n
    \n\nA Esclerose M\u00faltiple Secundaria Progresiva alc\u00e1nzase cando o grao de discapacidade persiste e\/ou empeora entre brotes<\/strong>. Este tipo de Esclerose M\u00faltiple pode aparecer despois dunha fase remitente-recorrente do proceso e consid\u00e9rase unha forma avanzada da EM. Entre un 30 e un 50% dos pacientes que sofren inicialmente a forma remitente-recorrente da EM, desenvolven a forma secundaria progresiva. Isto d\u00e1se tras un per\u00edodo de tempo que depende da idade de inicio<\/strong> e que adoita ocorrer entre os 35 e os 45 anos<\/strong>. A EM secundaria progresiva caracter\u00edzase por unha progresi\u00f3n continua con ou sen recidivas ocasionais, remisi\u00f3ns pouco importantes e fases de estabilidade.\n\n<\/div>\n<\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    progresiva recidivante (EMPR)<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n
    \n\n\u00c9 a forma menos com\u00fan, d\u00e1ndose nun 5% dos casos. Caracter\u00edzase por unha progresi\u00f3n constante e sen remisi\u00f3ns desde o comezo cunha clara superposici\u00f3n de brotes con ou sen recuperaci\u00f3n completa.\n\n<\/div>\n<\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    progresiva recidivante (EMPR)<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t
    Calc\u00falase que en Espa\u00f1a existen 47.000 persoas afectadas de EM, 700.000 en Europa e m\u00e1is de 2.500.000 no mundo.<\/h5>
    Actualmente <\/strong>desco\u00f1\u00e9cese a causa da Esclerose M\u00faltiple<\/strong>, polo que a\u00ednda non existe unha cura para a enfermidade, pero si existen varios <\/strong>tratamentos farmacol\u00f3xicos que poden modificar o curso<\/strong> da mesma e que melloran substancialmente a calidade de vida das persoas afectadas<\/strong><\/h5><\/div><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    esclerose m\u00faltiple A esclerose m\u00faltiple \u00e9 unha enfermidade cr\u00f3nica do Sistema Nervioso Central (SNC), que afecta, de maneira intermitente, \u00e1 sustancia branca (mielina) de medula espinal e ao cerebro. Nos lugares afectados alt\u00e9rase a vaina de mielina que recubre os nervios. Como consecuencia disto atr\u00e1sase ou se interrompe a comunicaci\u00f3n nerviosa, xa que a mielina […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-1093","page","type-page","status-publish","hentry"],"yoast_head":"\nEsclerose - ACEM Esclerosis<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esclerose - ACEM Esclerosis\" \/>\n<meta property=\"og:description\" content=\"esclerose m\u00faltiple A esclerose m\u00faltiple \u00e9 unha enfermidade cr\u00f3nica do Sistema Nervioso Central (SNC), que afecta, de maneira intermitente, \u00e1 sustancia branca (mielina) de medula espinal e ao cerebro. Nos lugares afectados alt\u00e9rase a vaina de mielina que recubre os nervios. Como consecuencia disto atr\u00e1sase ou se interrompe a comunicaci\u00f3n nerviosa, xa que a mielina […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl\" \/>\n<meta property=\"og:site_name\" content=\"ACEM Esclerosis\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T09:33:27+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/192.168.1.117:8086\/#organization\",\"name\":\"Acem Esclerosis\",\"url\":\"https:\/\/192.168.1.117:8086\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/192.168.1.117:8086\/#logo\",\"inLanguage\":\"es\",\"url\":\"https:\/\/acemesclerosis.org\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2021-09-27-at-14.06.43.jpeg\",\"contentUrl\":\"https:\/\/acemesclerosis.org\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2021-09-27-at-14.06.43.jpeg\",\"width\":1600,\"height\":592,\"caption\":\"Acem Esclerosis\"},\"image\":{\"@id\":\"https:\/\/192.168.1.117:8086\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/192.168.1.117:8086\/#website\",\"url\":\"https:\/\/192.168.1.117:8086\/\",\"name\":\"ACEM Esclerosis\",\"description\":\"Asociaci\\u00f3n Coru\\u00f1esa de Esclerosis M\\u00faltiple\",\"publisher\":{\"@id\":\"https:\/\/192.168.1.117:8086\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/192.168.1.117:8086\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#webpage\",\"url\":\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl\",\"name\":\"Esclerose - ACEM Esclerosis\",\"isPartOf\":{\"@id\":\"https:\/\/192.168.1.117:8086\/#website\"},\"datePublished\":\"2021-10-04T15:24:53+00:00\",\"dateModified\":\"2025-04-16T09:33:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/192.168.1.117:8086\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esclerose\"}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esclerose - ACEM Esclerosis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl","og_locale":"es_ES","og_type":"article","og_title":"Esclerose - ACEM Esclerosis","og_description":"esclerose m\u00faltiple A esclerose m\u00faltiple \u00e9 unha enfermidade cr\u00f3nica do Sistema Nervioso Central (SNC), que afecta, de maneira intermitente, \u00e1 sustancia branca (mielina) de medula espinal e ao cerebro. Nos lugares afectados alt\u00e9rase a vaina de mielina que recubre os nervios. Como consecuencia disto atr\u00e1sase ou se interrompe a comunicaci\u00f3n nerviosa, xa que a mielina […]","og_url":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl","og_site_name":"ACEM Esclerosis","article_modified_time":"2025-04-16T09:33:27+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/192.168.1.117:8086\/#organization","name":"Acem Esclerosis","url":"https:\/\/192.168.1.117:8086\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"https:\/\/192.168.1.117:8086\/#logo","inLanguage":"es","url":"https:\/\/acemesclerosis.org\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2021-09-27-at-14.06.43.jpeg","contentUrl":"https:\/\/acemesclerosis.org\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2021-09-27-at-14.06.43.jpeg","width":1600,"height":592,"caption":"Acem Esclerosis"},"image":{"@id":"https:\/\/192.168.1.117:8086\/#logo"}},{"@type":"WebSite","@id":"https:\/\/192.168.1.117:8086\/#website","url":"https:\/\/192.168.1.117:8086\/","name":"ACEM Esclerosis","description":"Asociaci\u00f3n Coru\u00f1esa de Esclerosis M\u00faltiple","publisher":{"@id":"https:\/\/192.168.1.117:8086\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/192.168.1.117:8086\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#webpage","url":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl","name":"Esclerose - ACEM Esclerosis","isPartOf":{"@id":"https:\/\/192.168.1.117:8086\/#website"},"datePublished":"2021-10-04T15:24:53+00:00","dateModified":"2025-04-16T09:33:27+00:00","breadcrumb":{"@id":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/acemesclerosis.org\/?page_id=1093&lang=gl#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/192.168.1.117:8086\/"},{"@type":"ListItem","position":2,"name":"Esclerose"}]}]}},"_links":{"self":[{"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/pages\/1093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1093"}],"version-history":[{"count":16,"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/pages\/1093\/revisions"}],"predecessor-version":[{"id":4736,"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=\/wp\/v2\/pages\/1093\/revisions\/4736"}],"wp:attachment":[{"href":"https:\/\/acemesclerosis.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}